To evaluate the quality of life and correlated factors in chronic myeloid leukemia patients undergoing long-term imatinib therapy. This was a cross-sectional study recruiting 383 chronic myeloid leukemia patients who presented criteria which included being at least 18 years old, positive BCR-ABL gene and undergoing IM therapy for at least 6 months. Quality of life was evaluated with the EORTC QLQ-C30 questionnaire and defined by EORTC group guidelines. Descriptive statistics, one-way ANOVA and multivariable linear regression test were used. P-value <0.05 was considered statistically significant. The mean age of patients was 46.78 (SD=14.58) years, with the prevalence of disease in the younger group. The mean time of diagnosis and that of imatinib treatment were 4.91 (SD=3.30) years and 4.00 (SD=3.11) years, respectively. Patients showed a significant reduction of Global Health status with the mean score of 68.48 (SD=15.19), a slight decline of functional scores and a notable increase in financial distress. Among symptoms, fatigue got the highest value, as well as pain and insomnia. Multivariable analysis showed that age, income, and comorbidities were powerful factors independently associated with Global health status. However, if fatigue was one of the key aspects analysed, it was the only factor statistically significantly associated with Global Health status (p-value=0.001). Regarding fatigue, age and comorbidities were the two most associated factors. The quality of life of chronic myeloid leukemia patients using imatinib was significantly reduced. Fatigue, age, income, and comorbidities were the main factors associated with Global Health status.